Axium Healthcare Pharmacy to Begin Dispensing Otezla®: the First FDA Approved Oral Therapy for the Treatment of Adults with Psoriatic Arthritis
Lake Mary, FL (PRWEB) April 04, 2014 -- Axium Healthcare Pharmacy announced today that it will begin to dispense Otezla®, the new oral therapy for the treatment of adults with active psoriatic arthritis (PsA). Axium is one of a limited number of specialty pharmacies selected by drug manufacturer Celgene to dispense Otezla®, which was approved by the FDA on March 21.
PsA is an inflammatory type of arthritis that occurs in 10 percent to 30 percent of people with psoriasis. It occurs when the immune system attacks the joints and causes inflammation. In clinical trials, PsA patients treated with Otezla® showed improvements in the signs and symptoms of PsA including tender and swollen joints, as well as physical function.
Psoriatic arthritis is a complex condition. As a specialty pharmacy, Axium, along with medications like Otezla®, is paving the way for better outcomes for patients with psoriatic arthritis. Axium’s clinical expertise in psoriatic arthritis, combined with its world-class ‘helping hand’ therapy management programs, helps to ensure that patients can maximize the benefits of their Otezla® treatment.
Prescribing information for Otezla® can be found online at http://www.otezla.com.
About Axium Healthcare Pharmacy
Founded in 2000, Axium Healthcare Pharmacy, Inc. is a nationwide provider of specialty pharmacy services. A wholly-owned subsidiary of The Kroger Company, Axium provides drug therapies and patient support services to treat chronic, genetic, and other complex conditions such as Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, and a number of others.
For more information, contact Axium Healthcare Pharmacy at 888.315.3395 or visit http://www.axiumhealthcare.com.
Wendy Bacigalupi, Legacy DNA Marketing Group for Axium Healthcare Pharmacy, http://www.axiumhealthcare.com, +1 407-889-8848, [email protected]
Share this article